Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406645 | 1.00 | LTA4H (0.44) | LTA4HNPY5RATMFPR2MAPK1 | |
| SCHEMBL5411945 | 0.91 | ROCK2 (0.48) | LTA4HATMFPR2HDAC8 | |
| SCHEMBL5411954 | 0.91 | ROCK2 (0.48) | LTA4HATMFPR2HDAC8 | |
| SCHEMBL5414349 | 0.91 | ROCK2 (0.48) | LTA4HATMFPR2HDAC8 | |
| SCHEMBL5414417 | 0.87 | ROCK2 (0.46) | ATMFPR2 | |
| SCHEMBL5414408 | 0.87 | ROCK2 (0.46) | ATMFPR2 | |
| SCHEMBL8296808 | 0.85 | LTA4H (0.59) | LTA4HNPY5RFPR2MAPK1TACR2 | |
| SCHEMBL5403766 | 0.81 | FPR2 (0.46) | NPY5RFPR2MAPK1TACR2CYP2C9 | |
| SCHEMBL5403771 | 0.81 | FPR2 (0.46) | NPY5RFPR2MAPK1TACR2CYP2C9 | |
| SCHEMBL5403755 | 0.81 | FPR2 (0.46) | NPY5RFPR2MAPK1TACR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | LTA4H 2015/4885NPY5R 2160/4885ATM 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.